{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TDF%2FFTC&page=14", "query": { "intervention": "TDF/FTC", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 352, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TDF%2FFTC&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TDF%2FFTC&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T04:38:44.238Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01234116", "title": "Post-Exposure Prophylaxis in Health Care Workers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "emtricitabine/tenofovir disoproxil fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2011-02", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-19T04:38:44.238Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234116" }, { "nct_id": "NCT01214759", "title": "Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Truvada", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2011-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-10-19T04:38:44.238Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01214759" }, { "nct_id": "NCT04388904", "title": "Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Crofoot Research Center, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2021-09-01", "completion_date": "2024-04-05", "has_results": false, "last_update_posted_date": "2024-04-26", "last_synced_at": "2026-10-19T04:38:44.238Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04388904" }, { "nct_id": "NCT02656511", "title": "Immediate Initiation of Antiretroviral Therapy During \"Hyperacute\" HIV Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Emtricitabine/Tenofovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2015-12", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-19T04:38:44.238Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02656511" }, { "nct_id": "NCT01003990", "title": "Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Atazanavir/Ritonavir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" }, { "name": "Lopinavir/ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 710, "start_date": "2002-10", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-05-11", "last_synced_at": "2026-10-19T04:38:44.238Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01003990" }, { "nct_id": "NCT02572505", "title": "Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV", "Infertility" ], "interventions": [ { "name": "Truvada", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Missouri-Columbia", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 0, "start_date": "2015-11", "completion_date": "2017-09-20", "has_results": false, "last_update_posted_date": "2017-10-06", "last_synced_at": "2026-10-19T04:38:44.238Z", "location_count": 1, "location_summary": "Columbia, Missouri", "locations": [ { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02572505" }, { "nct_id": "NCT06544733", "title": "Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-Infection" ], "interventions": [ { "name": "Lepetegravir", "type": "DRUG" }, { "name": "Lenacapavir pacfosacil", "type": "DRUG" }, { "name": "Placebo to Match BVY", "type": "DRUG" }, { "name": "Bictegravir/emtricitabine/tenofovir alafenamide", "type": "DRUG" }, { "name": "Lepetegravir/Lenacapavir pacfosacil FDC", "type": "DRUG" }, { "name": "Placebo to Match GS1720/GS-4182 FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 675, "start_date": "2024-08-20", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-19T04:38:44.238Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06544733" }, { "nct_id": "NCT02603107", "title": "Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV/co", "type": "DRUG" }, { "name": "DRV/co", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 578, "start_date": "2015-11-20", "completion_date": "2019-12-23", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-10-19T04:38:44.238Z", "location_count": 63, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603107" }, { "nct_id": "NCT04870671", "title": "Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "HIV/AIDS", "Adherence, Medication", "Drug Use" ], "interventions": [ { "name": "Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Virginia Medical School", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 14, "start_date": "2021-03-25", "completion_date": "2023-01-31", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-19T04:38:44.238Z", "location_count": 1, "location_summary": "Norfolk, Virginia", "locations": [ { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04870671" }, { "nct_id": "NCT05630755", "title": "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DOR/ISL", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to DOR/ISL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 514, "start_date": "2023-02-17", "completion_date": "2028-08-04", "has_results": true, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-10-19T04:38:44.238Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05630755" } ] }